National directives in terms of stem cell research "provide ethical and scientific indications". They provide a framework for research and clinical trials in India through the introduction of restrictions.
Other restrictions. Clinical trials using differentiated cells obtained from human embryo stem cells and IPS cells must be authorised by the Drug Controller General of India (DCGI). The importing of "drugs", including therapeutic products and cells must be authorised in advance by the DCGI.
Conversely, research comprising the introduction of human embryo stem cells or IPS in animals is authorised "if the human stem cells significantly contribute to the development of the animal’s brain or gonads".
These directives have been compiled by the Indian Council of Medical Research (ICMR) and the Department of Biotechnology (DBT), and announced by the Minister for Health.